What's breaking now, across thousands of outlets.
Lab research suggests the little-studied peptide can form amyloid clumps and may damage neurons, but its role in Alzheimer’s patients remains unproven.
We haven't written up this one. Inc. has the full story — the link below goes straight to it.
Does a nurse want a different kind of partner than an engineer? In a study of nearly 2,000 adults across seven countries, the industry people worked in had almost no link to what they prioritized in a…
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain.
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
Breast cancer continues to dominate the caseload at the oncology unit of the Tamale Teaching Hospital (TTH), with 44 new cases recorded in the first half of the year.
A team led by Harvard Medical School researchers at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute has developed a faster way to identify and engineer cancer-fighting therapies.
Dr. Katie S. Davis, a psychologist specializing in childhood learning disorders, believes some parents are rushing to diagnose their kids.
